NanoSyrinx in Parliament

Our Founder and CEO, Joe Healey, was invited by the Parliamentary and Scientific Committee (P&SC – https://www.scienceinparliament.org.uk/) to discuss the future and potential of Synthetic Biology for the UK and for human health.

The UK has a stated (and laudable) ambition to become a “Scientific Superpower”, and Synthetic Biology is intimately tied to that vision. It was a cornerstone of the industrial strategy under previous leadership, and is still very much at the forefront of current science policy thinking.

The panel, was organised by SynBioBeta (the largest synthetic biology community and advocacy group) and Bit.Bio (a UK ‘cell programming’ company) with the P&SC. Whilst the focus of the discussion was particularly what Synthetic Biology could offer for human health, a wide range of topics were covered including synbio for sustainability and Net Zero, as well as a discussion about what the UK entrepreneurship ecosystem needs in order to thrive.


The panel was chaired by Stephen Metcalfe MP (South Basildon and East Thurrock), and the speakers included (pictured left to right above):

  • Mark Kotter, CEO of Bit.bio

  • Sara Holland, Patent attorney at Potter Clarkson specialising in synbio IP

  • Stephen Metcalfe MP, chair of the session

  • Fiona Mischel, Director of Human Health content at SynBioBeta

  • Joe Healey, Founder and CEO of NanoSyrinx

Read more news

JPM week 2024: NanoSyrinx highlighted in GEN

NanoSyrinx CEO Joe Healey, and CBO James Lapworth attended the JP Morgan Healthcare conference in San Francisco last week. Among a great week of meetings with collaborators, investors and partners, they sat down with Jonathan Grinstein PhD, a writer for GEN Edge, and spoke about the journey the company had been on and the outlook […]

Read more
Anthony Johnson, NanoSyrinx NED

NanoSyrinx appoints Anthony Johnson as Non-Executive Director

Coventry, UK, 10 November 2023: NanoSyrinx, a synthetic biology company developing a novel platform for targeted intracellular delivery of biologic therapeutics, today announced Anthony Johnson, M. D., has joined its Board as Non-Executive Director. Tony’s appointment forms part of the Company’s ongoing strategy to expand and strengthen its leadership team as the Company prepares for […]

Read more

NanoSyrinx to feature in PwC’s Life Sciences Future50 Report

We are delighted to be showcased as one of the 50 companies in PwC UK’s  ‘Life Sciences Future 50’ report, illustrating the world-class science and innovation being led by the UK’s life sciences sector to solve some of the most important challenges in scientific research and human healthcare. Find out more here: https://bit.ly/3Fnw379

Read more